牙周基础治疗对慢性肾病伴牙周炎患者肾脏预后的影响
本研究为优效性随机对照试验,纳入200例慢性肾病(CKD)合并牙周炎患者,随机分为牙周基础治疗组和仅口腔卫生指导组。结果显示,6个月时干预组尿微量白蛋白/肌酐比值(UACR)显著优于对照组(GMR=0.105),估算肾小球滤过率(eGFR)显著升高(平均差8.019),尿红细胞计数和尿蛋白/肌酐比值显著降低,提示牙周基础治疗可改善蛋白尿和血尿。
要点
- 牙周基础治疗可显著降低CKD伴牙周炎患者的蛋白尿和血尿。
- 干预6个月后eGFR显著提升,胱抑素C显著下降。
- 牙周健康管理可作为CKD综合管理的辅助策略。
核心结论
- 牙周基础治疗能有效改善CKD合并牙周炎患者的蛋白尿和血尿。
- 牙周基础治疗对提升eGFR和降低CysC有积极影响。
- 牙周健康管理可作为CKD患者综合管理的重要辅助手段。
研究设计与样本
- 采用优效性随机对照试验,200例CKD合并牙周炎患者按1∶1随机分为研究组和对照组各100例。
- 研究组接受规范的牙周基础治疗,对照组仅进行口腔卫生指导。
- 于基线及治疗后1、3、6个月收集血尿样本检测相关指标。
- 统计分析遵循意向性分析原则,采用多重插补处理缺失值并建立线性混合模型。
主要发现
- 随访6个月时研究组UACR显著优于对照组,组间几何均值比(GMR)为0.105(95%CI:0.076~0.145,P<0.001)。
- 6个月时研究组eGFR显著高于对照组,组间平均差为8.019(95%CI:4.784~11.254,P<0.001)。
- URBC及UPCR组间GMR分别为0.291(95%CI:0.203~0.419,P<0.001)和0.216(95%CI:0.172~0.271,P<0.001)。
- CysC在6个月时组间GMR为0.750(95%CI:0.681~0.827,P<0.001)。
- 两组间尿素氮、Scr、尿酸及HCO3-在研究期间差异均无统计学意义(均P>0.05)。
关键数值与推荐
- 主要终点为6个月时UACR组间GMR=0.105(95%CI:0.076~0.145,P<0.001)。
- 次要终点6个月时eGFR组间平均差=8.019(95%CI:4.784~11.254,P<0.001)。
- URBC组间GMR=0.291(95%CI:0.203~0.419,P<0.001),UPCR组间GMR=0.216(95%CI:0.172~0.271,P<0.001)。
- CysC组间GMR=0.750(95%CI:0.681~0.827,P<0.001)。
临床怎么用
- 对CKD合并牙周炎患者,可考虑实施规范的牙周基础治疗以改善肾脏相关指标。
- 牙周基础治疗可作为CKD患者综合管理的辅助手段,关注蛋白尿和血尿的改善。
- 治疗随访中应监测UACR、eGFR、URBC、UPCR及CysC等指标变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the effect of initial periodontal therapy on renal function related indicators in patients with chronic kidney disease (CKD) and periodontitis, with a special focus on evaluating the improvement in proteinuria and hematuria. Methods: This superiority randomized controlled trial involved 200 patients with CKD and periodontitis, recruited from May 2024 to January 2025 at the department of nephrology and referred to the Department of Stomatology at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, who were randomly assigned (1∶1) to either the intervention group (n=100) or the control group (n=100) using a computer-generated random sequence. The intervention group received standardized initial periodontal therapy, while the control group received only oral hygiene instruction. Blood and urine samples were collected from both groups at baseline and at 1, 3 and 6 months post-treatment to measure indicators including estimated glomerular filtration rate (eGFR), serum creatinine (Scr), blood urea nitrogen (BUN), uric acid (UA), bicarbonate (HCO3-), cystatin C (CysC), urinary albumin-to-creatinine ratio (UACR), urinary protein-to-creatinine ratio (UPCR), urinary creatinine (UCR), urinary microalbumin (UMA), urinary total protein (UTP), urinary red blood cell count (URBC), and dipstick results for hematuria and proteinuria. Statistical analysis followed the intention-to-treat (ITT) principle, with missing data handled by multiple imputation (MI) and analyzed using linear mixed models (LMM). P values were adjusted for multiple comparisons using the Bonferroni correction. Results: Baseline characteristics, including age, sex, body mass index (BMI), primary disease distribution, and renal laboratory parameters, were well-balanced between the two groups (P>0.05). At the 6-month primary endpoint, UACR in the intervention group was significantly better than that in the control group, with a between-group geometric mean ratio (GMR) of 0.105 (95%CI: 0.076-0.145, P<0.001). For secondary endpoints at 6 months, eGFR was significantly higher in the intervention group than in the control group, with a mean difference (MD) of 8.019 (95%CI: 4.784-11.254, P<0.001). The between-group GMRs for URBC and UPCR were 0.291 (95%CI: 0.203-0.419, P<0.001) and 0.216 (95%CI: 0.172-0.271, P<0.001), respectively. In addition, the between-group GMR of CysC at 6 months was 0.750 (95%CI: 0.681-0.827, P<0.001). No statistically significant between-group differences were observed for BUN, Scr, UA, or HCO3- during the study period (all P>0.05). Conclusions: This study demonstrates that initial periodontal therapy can effectively reduce proteinuria and hematuria in patients with CKD and periodontitis. It also has a positive impact on increasing eGFR and decreasing CysC. These findings suggest that periodontal health management could serve as a valuable adjunctive strategy in the comprehensive management of patients with CKD. 目的: 探讨牙周基础治疗对慢性肾病(CKD)伴牙周炎患者肾功能相关指标的影响,评估其对蛋白尿及血尿的改善效果。 方法: 采用优效性随机对照研究方法,通过计算机生成随机数序列,将2024年5月至2025年1月就诊于华中科技大学同济医学院附属同济医院肾内科并转诊至该院口腔科,符合纳排标准的200例CKD合并牙周炎患者按1∶1比例随机分为研究组和对照组。研究组接受规范的牙周基础治疗,对照组仅进行口腔卫生指导。分别于基线及治疗后1、3、6个月收集两组患者的血液及尿液样本,检测估算肾小球滤过率(eGFR)、血清肌酐(Scr)、尿素氮、尿酸、碳酸氢根(HCO3-)、胱抑素C(CysC)、尿微量白蛋白/肌酐比值(UACR)、尿微量总蛋白/肌酐比值(UPCR)、尿肌酐、尿微量白蛋白(UMA)、尿微量总蛋白(UTP)、尿红细胞计数(URBC)、血尿和蛋白尿试纸检测等指标。统计分析遵循意向性分析原则,采用多重插补处理缺失值并建立线性混合模型。组间多时间点比较采用Bonferroni法进行多重比较校正。 结果: 两组患者基线时年龄、性别、体重指数、原发病分布、尿液和肾功能生化相关实验室指标等方面差异均无统计学意义(均P>0.05)。在随访6个月的主要评价终点,研究组主要终点指标UACR显著优于对照组,组间几何均值比(GMR)为0.105(95%CI:0.076~0.145,P<0.001)。次要终点指标方面,随访6个月时研究组eGFR水平显著高于对照组,组间平均差为8.019(95%CI:4.784~11.254,P<0.001);URBC及UPCR组间GMR分别为0.291(95%CI:0.203~0.419,P<0.001)和0.216(95%CI:0.172~0.271,P<0.001)。此外,CysC在6个月时组间GMR为0.750(95%CI:0.681~0.827,P<0.001),两组间尿素氮、Scr、尿酸及HCO3-在研究期间差异均无统计学意义(均P>0.05)。 结论: 牙周基础治疗能有效改善CKD合并牙周炎患者的蛋白尿和血尿,并对提升eGFR和降低CysC有积极影响,提示牙周健康管理可作为CKD患者综合管理的重要辅助手段。.
引用
- Sun RM, Abulaiti G, Huang HT, et al. [Effects of initial periodontal therapy on renal prognosis in patients with chronic kidney disease and periodontitis]. Zhonghua Kou Qiang Yi Xue Za Zhi. 2026. PMID: 41913608. doi:10.3760/cma.j.cn112144-20251210-00502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。